Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain

Journal of Virology

Volumn 83, Issue 11, 2009, Pages 5430-5441

  Gray, Lachlan ^a,b   Roche, Michael ^a,c   Churchill, Melissa J ^a,c   Sterjovski, Jasminka ^a,c   Ellett, Anne ^a   Poumbourios, Pantelis ^a   Sheffief, Shameem ^d   Wang, Bin ^d   Saksena, Nitin ^d   Purcell, Damian F J ^b   Wesselingh, Steven ^b,c   Cunningham, Anthony L ^d   Brew, Bruce J ^e   Gabuzda, Dana ^f,g   Gorry, Paul R ^a,b,c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EXTRACELLULAR LOOP 1; EXTRACELLULAR LOOP 2; EXTRACELLULAR LOOP 3; GLYCOPROTEIN GP 120; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD; BRAIN; CELL LINE; CELL LINEAGE; CELL TYPE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOID TISSUE; MACROPHAGE; MONOCYTE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT; SPLEEN; T LYMPHOCYTE; TROPICS; VIROGENESIS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS ISOLATION; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; CELL CULTURE; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; BRAIN; CELLS, CULTURED; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; ORGAN SPECIFICITY; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; VIRUS INTERNALIZATION;

EID: 66149133705     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02648-08     Document Type: Article

References (75)

1. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958. (Pubitemid 26234510)
2. Blankson, J. N., D. Persaud, and R. F. Siliciano. 2002. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53:557-593. (Pubitemid 34177896)
3. Braun, P., and F. Wiesmann. 2007. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. Eur. J. Med. Res. 12:463-472. (Pubitemid 350011459)
4. Brelot, A., N. Heveker, K. Adema, M. J. Hosie, B. Willett, and M. Alizon. 1999. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J. Virol. 73:2576-2586. (Pubitemid 29135641)
5. Cardozo, T., T. Kimura, S. Philpott, B. Weiser, H. Burger, and S. Zolla- Pazner. 2007. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retrovir. 23:415-426. (Pubitemid 46608562)
6. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148. (Pubitemid 26231178)
7. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
8. Cormier, E. G., and T. Dragic. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76:8953-8957.
9. Cysique, L. A., P. Maruff, and B. J. Brew. 2004. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch. Neurol. 61:1699-1704. (Pubitemid 39463428)
10. Di Stefano, M., S. Wilt, F. Gray, M. Dubois-Dalcq, and F. Chiodi. 1996. HIV type 1 V3 sequences and the development of dementia during AIDS. AIDS Res. Hum. Retrovir. 12:471-476. (Pubitemid 26104463)
11. Doms, R. W. 2000. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276:229-237.
12. Doms, R. W., and D. Trono. 2000. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 14:2677-2688. (Pubitemid 32531194)
13. Doranz, B. J., Z. H. Lu, J. Rucker, T. Y. Zhang, M. Sharron, Y. H. Cen, Z. X. Wang, H. H. Guo, J. G. Du, M. A. Accavitti, R. W. Doms, and S. C. Peiper. 1997. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71:6305-6314. (Pubitemid 27355283)
14. Doranz, B. J., M. J. Orsini, J. D. Turner, T. L. Hoffman, J. F. Berson, J. A. Hoxie, S. C. Peiper, L. F. Brass, and R. W. Doms. 1999. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J. Virol. 73:2752-2761. (Pubitemid 29135661)
15. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
16. Dunfee, R., E. Thomas, P. R. Gorry, J. Wang, P. Ancuta, and D. Gabuzda. 2006. Mechanisms of HIV-1 neurotropism. Curr. HIV Res. 4:267-278. (Pubitemid 44027717)
17. Dunfee, R. L., E. R. Thomas, P. R. Gorry, J. Wang, J. Taylor, K. Kunstman, S. M. Wolinsky, and D. Gabuzda. 2006. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. USA 103:15160-15165. (Pubitemid 44583181)
18. Ellery, P. J., E. Tippett, Y. L. Chiu, G. Paukovics, P. U. Cameron, A. Solomon, S. R. Lewin, P. R. Gorry, A. Jaworowski, W. C. Greene, S. Sonza, and S. M. Crowe. 2007. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178:6581-6589. (Pubitemid 46717442)
19. Etemad-Moghadam, B., Y. Sun, E. K. Nicholson, M. Fernandes, K. Liou, R. Gomila, J. Lee, and J. Sodroski. 2000. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 74:4433-4440. (Pubitemid 30214453)
20. Farzan, M., H. Choe, L. Vaca, K. Martin, Y. Sun, E. Desjardins, N. Ruffing, L. Wu, R. Wyatt, N. Gerard, C. Gerard, and J. Sodroski. 1998. A tyrosinerich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 72:1160-1164. (Pubitemid 28116898)
21. Farzan, M., T. Mirzabekov, P. Kolchinsky, R. Wyatt, M. Cayabyab, N. P. Gerard, C. Gerard, J. Sodroski, and H. Choe. 1999. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96:667-676. (Pubitemid 29122809)
22. Fatkenheuer, G., M. Nelson, A. Lazzarin, I. Konourina, A. I. Hoepelman, H. Lampiris, B. Hirschel, P. Tebas, F. Raffi, B. Trottier, N. Bellos, M. Saag, D. A. Cooper, M. Westby, M. Tawadrous, J. F. Sullivan, C. Ridgway, M. W. Dunne, S. Felstead, H. Mayer, and E. van der Ryst. 2008. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359:1442-1455.
23. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877. (Pubitemid 26154590)
24. Gabuzda, D., and J. Wang. 2000. Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. J. Neurovirol. 6(Suppl. 1):S24-S32. (Pubitemid 30342774)
25. Gabuzda, D., and J. Wang. 1999. Chemokine receptors and virus entry in the central nervous system. J. Neurovirol. 5:643-658. (Pubitemid 30032090)
26. Gao, F., S. G. Morrison, D. L. Robertson, C. L. Thornton, S. Craig, G. Karlsson, J. Sodroski, M. Morgado, B. Galvao-Castro, H. von Briesen, et al. 1996. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J. Virol. 70:1651-1667. (Pubitemid 26062925)
27. Gartner, S., P. Markovits, D. M. Markovitz, R. F. Betts, and M. Popovic. 1986. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 256:2365-2371. (Pubitemid 17174464)
28. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219. (Pubitemid 16008118)
29. Gonzalez-Scarano, F., and J. Martin-Garcia. 2005. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5:69-81. (Pubitemid 40070332)
30. Gorry, P. R., G. Bristol, J. A. Zack, K. Ritola, R. Swanstrom, C. J. Birch, J. E. Bell, N. Bannert, K. Crawford, H. Wang, D. Schols, E. De Clercq, K. Kunstman, S. M. Wolinsky, and D. Gabuzda. 2001. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J. Virol. 75:10073-10089. (Pubitemid 32948038)
31. Gorry, P. R., M. Churchill, S. M. Crowe, A. L. Cunningham, and D. Gabuzda. 2005. Pathogenesis of macrophage tropic HIV. Curr. HIV Res. 3:53-60.
32. Gorry, P. R., R. L. Dunfee, M. E. Mefford, K. Kunstman, T. Morgan, J. P. Moore, J. R. Mascola, K. Agopian, G. H. Holm, A. Mehle, J. Taylor, M. Farzan, H. Wang, P. Ellery, S. J. Willey, P. R. Clapham, S. M. Wolinsky, S. M. Crowe, and D. Gabuzda. 2007. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Δ32 heterozygote. Virology 362:163-178. (Pubitemid 46617680)
33. Gorry, P. R., J. Taylor, G. H. Holm, A. Mehle, T. Morgan, M. Cayabyab, M. Farzan, H. Wang, J. E. Bell, K. Kunstman, J. P. Moore, S. M. Wolinsky, and D. Gabuzda. 2002. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 76:6277-6292. (Pubitemid 34556323)
34. Gray, L., M. J. Churchill, N. Keane, J. Sterjovski, A. M. Ellett, D. F. J. Purcell, P. Poumbourios, C. Kol, B. Wang, N. Saksena, S. L. Wesselingh, P. Price, M. French, D. Gabuzda, and P. R. Gorry. 2006. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5Δ32 allele. J. Virol. 80:3684-3691.
35. Gulick, R. M., J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, J. Nadler, B. Clotet, A. Karlsson, M. Wohlfeiler, J. B. Montana, M. McHale, J. Sullivan, C. Ridgway, S. Felstead, M. W. Dunne, E. van der Ryst, and H. Mayer. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
36. Gulick, R. M., Z. Su, C. Flexner, M. D. Hughes, P. R. Skolnik, T. J. Wilkin, R. Gross, A. Krambrink, E. Coakley, W. L. Greaves, A. Zolopa, R. Reichman, C. Godfrey, M. Hirsch, and D. R. Kuritzkes. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 196:304-312. (Pubitemid 47047471)
37. Hoffman, T. L., and R. W. Doms. 1999. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol. Membr. Biol. 16:57-65. (Pubitemid 29179338)
38. Huang, C. C., M. Tang, M. Y. Zhang, S. Majeed, E. Montabana, R. L. Stanfield, D. S. Dimitrov, B. Korber, J. Sodroski, I. A. Wilson, R. Wyatt, and P. D. Kwong. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
39. Jensen, M. A., F. S. Li, A. B. van 't Wout, D. C. Nickle, D. Shriner, H. X. He, S. McLaughlin, R. Shankarappa, J. B. Margolick, and J. I. Mullins. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77:13376-13388.
40. Karlsson, I., L. Antonsson, Y. Shi, M. Oberg, A. Karlsson, J. Albert, B. Olde, C. Owman, M. Jansson, and E. M. Fenyo. 2004. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J. Virol. 78:11807-11815. (Pubitemid 39390767)
41. Kaul, M., G. A. Garden, and S. A. Lipton. 2001. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988-994. (Pubitemid 32335850)
42. Korber, B. T., K. J. Kunstman, B. K. Patterson, M. Furtado, M. M. McEvilly, R. Levy, and S. M. Wolinsky. 1994. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68:7467-7481. (Pubitemid 24328802)
43. Laakso, M. M., F. H. Lee, B. Haggarty, C. Agrawal, K. M. Nolan, M. Biscone, J. Romano, A. P. Jordan, G. J. Leslie, E. G. Meissner, L. Su, J. A. Hoxie, and R. W. Doms. 2007. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 3:e117.
44. Landovitz, R. J., J. B. Angel, C. Hoffmann, H. Horst, M. Opravil, J. Long, W. Greaves, and G. Fatkenheuer. 2008. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 198:1113-1122.
45. Letendre, S., J. Marquie-Beck, E. Capparelli, B. Best, D. Clifford, A. C. Collier, B. B. Gelman, J. C. McArthur, J. A. McCutchan, S. Morgello, D. Simpson, I. Grant, and R. J. Ellis. 2008. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65:65-70.
46. Low, A. J., W. Dong, D. Chan, T. Sing, R. Swanstrom, M. Jensen, S. Pillai, B. Good, and P. R. Harrigan. 2007. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21:F17-F24. (Pubitemid 47329758)
47. McGavin, C. H., S. A. Land, K. L. Sebire, D. J. Hooker, A. D. Gurusinghe, and C. J. Birch. 1996. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue. AIDS 10:47-53. (Pubitemid 26016402)
48. Mefford, M. E., P. R. Gorry, K. Kunstman, S. M. Wolinsky, and D. Gabuzda. 2008. Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS Res. Hum. Retrovir. 24:1215-1220.
49. Meucci, O., A. Fatatis, A. A. Simen, T. J. Bushell, P. W. Gray, and R. J. Miller. 1998. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl. Acad. Sci. USA 95:14500-14505. (Pubitemid 28549396)
50. Ohagen, A., A. Devitt, K. J. Kunstman, P. R. Gorry, P. P. Rose, B. Korber, J. Taylor, R. Levy, R. L. Murphy, S. M. Wolinsky, and D. Gabuzda. 2003. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J. Virol. 77:12336-12345.
51. Perry, S. W., J. P. Norman, and H. A. Gelbard. 2005. Adjunctive therapies for HIV-1 associated neurologic disease. Neurotox. Res. 8:161-166.
52. Pierson, T., J. McArthur, and R. F. Siliciano. 2000. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18:665-708. (Pubitemid 30365394)
53. Platt, E. J., S. E. Kuhmann, P. P. Rose, and D. Kabat. 2001. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region. J. Virol. 75:12266-12278. (Pubitemid 33115899)
54. Platt, E. J., D. M. Shea, P. P. Rose, and D. Kabat. 2005. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosinesulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J. Virol. 79:4357-4368. (Pubitemid 40388373)
55. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864. (Pubitemid 28175522)
56. Reddy, R. T., C. L. Achim, D. A. Sirko, S. Tehranchi, F. G. Kraus, F. Wong-Staal, and C. A. Wiley. 1996. Sequence analysis of the V3 loop in brain and spleen of patients with HIV encephalitis. AIDS Res. Hum. Retrovir. 12:477-482. (Pubitemid 26104464)
57. Resch, W., N. Hoffman, and R. Swanstrom. 2001. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288: 51-62. (Pubitemid 32846473)
58. Schurmann, D., G. Fatkenheuer, J. Reynes, C. Michelet, F. Raffi, J. van Lier, M. Caceres, A. Keung, A. Sansone-Parsons, L. M. Dunkle, and C. Hoffmann. 2007. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21:1293-1299. (Pubitemid 46883483)
59. Sharpless, N. E., W. A. O'Brien, E. Verdin, C. V. Kufta, I. S. Chen, and M. Dubois-Dalcq. 1992. Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J. Virol. 66:2588-2593.
60. Shimizu, N., Y. Haraguchi, Y. Takeuchi, Y. Soda, K. Kanbe, and H. Hoshino. 1999. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology 259:324-333. (Pubitemid 29393383)
61. Shimizu, N. S., N. G. Shimizu, Y. Takeuchi, and H. Hoshino. 1994. Isolation and characterization of human immunodeficiency virus type 1 variants infectious to brain-derived cells: detection of common point mutations in the V3 region of the env gene of the variants. J. Virol. 68:6130-6135. (Pubitemid 24258639)
62. + T cells. Nat. Med. 9:727-728.
63. Siliciano, R. F. 1999. Latency and reservoirs for HIV-1. AIDS 13(Suppl. A):S49-S58.
64. Smit, T. K., B. Wang, T. Ng, R. Osborne, B. Brew, and N. K. Saksena. 2001. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): evidence for neurotropic HIV variants. Virology 279:509-526. (Pubitemid 34161115)
65. Sterjovski, J., M. J. Churchill, A. Ellett, L. R. Gray, M. J. Roche, R. L. Dunfee, D. F. Purcell, N. Saksena, B. Wang, S. Sonza, S. L. Wesselingh, I. Karlsson, E. M. Fenyo, D. Gabuzda, A. L. Cunningham, and P. R. Gorry. 2007. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4:89.
66. Tagat, J. R., S. W. McCombie, D. Nazareno, M. A. Labroli, Y. Xiao, R. W. Steensma, J. M. Strizki, B. M. Baroudy, K. Cox, J. Lachowicz, G. Varty, and R. Watkins. 2004. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy- 1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl] -4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 47:2405-2408.
67. Thomas, E. R., R. L. Dunfee, J. Stanton, D. Bogdan, J. Taylor, K. Kunstman, J. E. Bell, S. M. Wolinsky, and D. Gabuzda. 2007. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 360:105-119. (Pubitemid 46319229)
68. Walker, D. K., S. Abel, P. Comby, G. J. Muirhead, A. N. Nedderman, and D. A. Smith. 2005. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33:587-595. (Pubitemid 40393203)
69. Walker, D. K., S. J. Bowers, R. J. Mitchell, M. J. Potchoiba, C. M. Schroeder, and H. F. Small. 2008. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 38:1330-1339.
70. Xu, S., X. Huang, H. Xu, and C. Zhang. 2007. Improved prediction of coreceptor usage and phenotype of HIV-1 based on combined features of V3 loop sequence using random forest. J. Microbiol. 45:441-446. (Pubitemid 350023379)
71. Yang, X., V. Tomov, S. Kurteva, L. Wang, X. Ren, M. K. Gorny, S. Zolla- Pazner, and J. Sodroski. 2004. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J. Virol. 78:12975-12986. (Pubitemid 39507805)
72. Yang, X., R. Wyatt, and J. Sodroski. 2001. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75:1165-1171. (Pubitemid 32094675)
73. Yi, Y., S. N. Isaacs, D. A. Williams, I. Frank, D. Schols, E. De Clercq, D. L. Kolson, and R. G. Collman. 1999. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. J. Virol. 73:7117-7125. (Pubitemid 29383191)
74. Yi, Y., F. Shaheen, and R. G. Collman. 2005. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J. Virol. 79:1480-1486. (Pubitemid 40459095)
75. Zheng, J., A. Ghorpade, D. Niemann, R. L. Cotter, M. R. Thylin, L. Epstein, J. M. Swartz, R. B. Shepard, X. Liu, A. Nukuna, and H. E. Gendelman. 1999. Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia. J. Virol. 73:8256-8267. (Pubitemid 29441687)